Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cidoxepin

Next Previous
Search
Drug Profile

Cidoxepin

Latest Information Update: 03 Mar 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gideon Pharmaceuticals
  • Developer Elorac
  • Class Antiallergics; Dibenzoxepins; Oxepins; Skin disorder therapies; Small molecules; Xanthenes
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic urticaria
  • Discontinued Allergic rhinitis; Atopic dermatitis; Contact dermatitis

Most Recent Events

  • 03 Mar 2017 Phase-II development for Chronic-urticaria is ongoing in USA (PO)
  • 03 Mar 2017 Discontinued - Phase-II for Allergic rhinitis in USA (PO)
  • 03 Mar 2017 Elorac plans a phase III trial for Urticaria in USA (PO) (Elorac pipeline, March 2017)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top